masthead-news

News & Events

Categories

Reset Categories

Filter by Topics

AACR AMP ASCO Biomarker Discovery Bristol-Myers Squibb CDx Centre Leon Berard Clinical Biomarker CMDCAS Conference Conference Call Daiichi Sankyo Durviz ESHG FFPE Financial Results Forums Gamidor Genomeweb HTG HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBLCL Cell of Origin Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq System HTGEdgeSeq IAP IHC Illumina Immuno-Oncology ISO 13485 IVD Merck KGaA Molecular Profiling Nasdaq Nature Research Custom Media Webcast Nature.com NGS NSCLC Patents Platform comparison PMWC Presentation QIAGEN Reports RNA-Seq Sequencing Symposium Thermo Fisher Transcriptome VERI/O Laboratory Services Webinar WIN Consortium WIN Symposium
Reset Filter Reset All

HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial

TUCSON, Ariz., Aug. 09, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology will be used together with Illumina next-generation sequencing (NGS) in a clinical trial conducted by the Worldwide Innovative Networking Consortium (WIN) investigating a novel therapeutic approach using a combination of three targeted therapies for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC).

Read More

Posted on:
 

HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN

TUCSON, Ariz. and VENLO, the Netherlands, July 27, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications today announced the initiation of a second development program under the company’s Master Assay Development, Commercialization and Manufacturing Agreement (“Master Agreement”) with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NASDAQ:QGEN) (Frankfurt Stock Exchange:QIA) (“QIAGEN”). HTG EdgeSeq technology will be used in the program to develop gene expression profiling (“GEP”) assays for use with next-generation sequencing (“NGS”) technology in support of another pharmaceutical company’s therapeutic development and commercialization programs.

Read More

Posted on:
 

HTG Molecular Diagnostics to Hold 2017 Second Quarter Financial Results Conference Call on August 8, 2017

TUCSON, Ariz., July 18, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 second quarter financial results after market close on Tuesday, August 8, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Tuesday, August 8 to discuss these results and answer questions.

Read More

Posted on:
 

HTG Molecular Diagnostics Participating in WIN 2017 Symposium

TUCSON, Ariz., June 26, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced its participation in WIN 2017 Symposium, dedicated to Expediting Global Innovation in Precision Cancer Medicine, which is being held in Paris, France on June 26 and 27, 2017. HTG is an industry member of the Worldwide Innovative Networking (WIN) Consortium, whose mission is to rapidly translate personalized cancer medicine discoveries into standards of patient care worldwide. WIN is a non-profit global network of world-class academics, industries and patients’ advocates aiming to transform the practice of oncology and significantly improve survival and quality of life of cancer patients. HTG was actively recruited to the consortium to support gene expression profiling activities of its members, including WIN clinical trials that integrate RNA investigations in the clinical setting.

Read More

Posted on:
 

HTG Molecular Diagnostics to Hold 2017 First Quarter Results Conference Call on May 15, 2017

TUCSON, Ariz., May 01, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 first quarter results after market close on Monday, May 15, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, May 15 to discuss these results and answer questions.

Read More

Posted on:
 

HTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration

TUCSON, Ariz., April 24, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a research collaboration agreement with Instituto Valenciano de Oncología (IVO). The initial project, utilizing the HTG EdgeSeq Oncology Biomarker Panel, will focus on the development and validation of a breast cancer recurrence risk score, based on genes that are differentially expressed between patients with low and high risk of recurrence.

Read More

Posted on:
 

HTG Molecular Diagnostics and Centre Léon Bérard Enter Into Molecular Profiling Research Agreement

TUCSON, Ariz., April 17, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, announced that it has entered into a research agreement with Centre Léon Bérard, which provides the framework for molecular profiling studies aimed to advance precision medicine. The initial project utilizes the HTG EdgeSeq Oncology Biomarker Panel to retrospectively characterize immunologic profiles from advanced malignant tumor samples collected in the ProfiLER study (ClinicalTrials.gov identifier NCT01774409).

Read More

Posted on:
 

HTG Molecular Diagnostics Transfers Listing to The Nasdaq Capital Market

TUCSON, Ariz., April 17, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that, on April 12, 2017, the company received formal notice from The NASDAQ Stock Market LLC indicating that the Nasdaq Hearings Panel had granted the Company’s request to transfer the listing of HTG’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market based upon HTG’s compliance with all requirements for continued listing on the latter market. The intra-market transfer took effect upon the open of trading this morning, Monday, April 17, 2017.

Read More

Posted on:

Page last updated March 20, 2023